These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 35809868)

  • 1. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.
    Qi T; McGrath K; Ranganathan R; Dotti G; Cao Y
    Adv Drug Deliv Rev; 2022 Sep; 188():114421. PubMed ID: 35809868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches.
    Chaudhury A; Zhu X; Chu L; Goliaei A; June CH; Kearns JD; Stein AM
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S147-S159. PubMed ID: 33205434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans.
    Liu C; Ayyar VS; Zheng X; Chen W; Zheng S; Mody H; Wang W; Heald D; Singh AP; Cao Y
    Clin Pharmacol Ther; 2021 Mar; 109(3):716-727. PubMed ID: 33002189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development.
    Kast J; Nozohouri S; Zhou D; Yago MR; Chen PW; Ahamadi M; Dutta S; Upreti VV
    Clin Transl Sci; 2022 Sep; 15(9):2057-2074. PubMed ID: 35677992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
    Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
    J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deconvolution of clinical variance in CAR-T cell pharmacology and response.
    Kirouac DC; Zmurchok C; Deyati A; Sicherman J; Bond C; Zandstra PW
    Nat Biotechnol; 2023 Nov; 41(11):1606-1617. PubMed ID: 36849828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells.
    Holzinger A; Abken H
    Pharmacology; 2022; 107(9-10):446-463. PubMed ID: 35696994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T.
    Singh AP; Chen W; Zheng X; Mody H; Carpenter TJ; Zong A; Heald DL
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):362-376. PubMed ID: 33565700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology.
    Huang W; Li J; Liao MZ; Liu SN; Yu J; Jing J; Kotani N; Kamen L; Guelman S; Miles DR
    Clin Pharmacol Ther; 2022 Nov; 112(5):968-981. PubMed ID: 34888856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
    Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
    MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioanalytical Methods for Characterization of CAR-T Cellular Kinetics: Comparison of PCR Assays and Matrices.
    Masilamani M; Jawa V; Dai Y; Das R; Park A; Lamba M; Wu F; Zheng X; Lu E; Gleason C; Mack T; Mora J; Surapaneni S
    Clin Pharmacol Ther; 2023 Sep; 114(3):664-672. PubMed ID: 37422675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: Benefits and challenges.
    Sarikonda G; Pahuja A; Kalfoglou C; Burns K; Nguyen K; Ch'en IL; Pollner R; Tangri S; Dakappagari N
    Cytometry B Clin Cytom; 2021 Jan; 100(1):72-78. PubMed ID: 32573972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].
    Hanajiri R; Furukawa K; Nakashima M; Ushijima Y; Shimada K; Ishikawa Y; Terakura S; Murata M; Kiyoi H
    Rinsho Ketsueki; 2023; 64(3):167-174. PubMed ID: 37019669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19 CAR T cell product and disease attributes predict leukemia remission durability.
    Finney OC; Brakke HM; Rawlings-Rhea S; Hicks R; Doolittle D; Lopez M; Futrell RB; Orentas RJ; Li D; Gardner RA; Jensen MC
    J Clin Invest; 2019 May; 129(5):2123-2132. PubMed ID: 30860496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
    Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
    Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.